ARV FDF there is pricing pressure and there is significant price drop.
Bio is too small.
CDMO is lumpy and it is yet to reach critical mass. CDMO will grow only from next FY.
Non ARV API although good margins but its not consistent.
Agree worst is not over yet.
It will see more downside than upside.
Any upside can be used to book profit.
I think next 12-18 months can be used for trading, but if someone is looking for long term then they can purchase at any price. I think 280-300 is a good support.
Also one can wait to see monthly export data to get a pulse of quarterly results can be.
Subscribe To Our Free Newsletter |